Transcription

ICMJE Form for Disclosure of Potential Conflicts of InterestInstructionsThe purpose of this form is to provide readers of your manuscript with information about your other interests that couldinfluence how they receive and understand your work. The form is designed to be completed electronically and storedelectronically. It contains programming that allows appropriate data display. Each author should submit a separateform and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.1.Identifying information.2.The work under consideration for publication.This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of thework itself, from the initial conception and planning to the present. The requested information is about resources that you received,either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the workwithout receiving any financial support from any third party -- that is, the work was supported by funds from the same institution thatpays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received fundsfrom a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check"Yes".3.Relevant financial activities outside the submitted work.This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or thatgive the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entitythat could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor(EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancerin general, not just in the area of EGFR or lung cancer.Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior tosubmission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from theentity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted workshould also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could beperceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could beperceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations oracademic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involvedand drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.4.Intellectual Property.This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.5.Relationships not covered above.Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance ofpotentially influencing, what you wrote in the submitted work.Definitions.Entity: government agency, foundation, commercial sponsor,academic institution, etc.Grant: A grant from an entity, generally [but not always] paid to yourorganizationPersonal Fees: Monies paid to you for services rendered, generallyhonoraria, royalties, or fees for consulting , lectures, speakers bureaus,expert testimony, employment, or other affiliationsNon-Financial Support: Examples include drugs/equipmentsupplied by the entity, travel paid by the entity, writing assistance,administrative support, etc.BhattOther: Anything not covered under the previous three boxesPending: The patent has been filed but not issuedIssued: The patent has been issued by the agencyLicensed: The patent has been licensed to an entity, whetherearning royalties or notRoyalties: Funds are coming in to you or your institution due to yourpatent1

ICMJE Form for Disclosure of Potential Conflicts of InterestSection 1.Identifying Information1. Given Name (First Name)2. Surname (Last Name)3. DateDeepakBhatt26-September-20204. Are you the corresponding author? YesNo5. Manuscript TitleSotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure6. Manuscript Identifying Number (if you know it)20-30183Section 2.The Work Under Consideration for PublicationDid you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) forany aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation,statistical analysis, etc.)? YesAre there any relevant conflicts of interest?NoIf yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row.Excess rows can be removed by pressing the "X" button.Name of Institution/CompanyGrant? Personal Non-Financial OtherFees?Support?CommentsSanofi Chair of SOLOIST and SCOREDLexicon Pharmaceuticals Chair of SOLOIST and SCOREDSection 3.Relevant financial activities outside the submitted work.Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amountof compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need byclicking the "Add " box. You should report relationships that were present during the 36 months prior to publication. YesAre there any relevant conflicts of interest?NoIf yes, please fill out the appropriate information below.Name of EntityAmarinBhattGrant? Personal Non-Financial OtherFees?Support? ?CommentsResearch Funding; REDUCE-IT Chairand PI2

ICMJE Form for Disclosure of Potential Conflicts of InterestName of EntityGrant? Personal Non-Financial OtherFees?Support?AstraZeneca?Comments Research Funding; SAVOR-TIMI 53 coPI; THEMIS and THEMIS PCI co-Chairand co-PI; PEGASUS-TIMI 54Executive Committee; DECLARE-TIMI58 Executive CommitteeBristol-Myers Squibb Research Funding; PIEisai Research Funding; PIEthicon Research Funding; co-PI ofSTAMPEDEMedtronic Research Funding; SYMPLICITY HTN-3co-PI Research funding; ODYSSEYExecutive Steering Committee;SCORED and SOLOIST Chair Research Funding; co-PI and co-Chairof CHAMPION PLATFORM,CHAMPION PCI, and CHAMPIONPHOENIXsanofi aventisThe Medicines CompanyFlowCoPLx Pharma Takeda Unfunded research collaboration Research Funding; Scientific AdvisoryBoard Unfunded research collaborationDuke Clinical Research Institute Data Monitoring Committees; ClinicalTrial Steering CommitteesMayo Clinic Data Monitoring CommitteePopulation Health Research Institute Data Monitoring Committees Senior Associate Editor, Clinical Trialsand News, ACC.org; Vice-Chair,Accreditation Committee; Trustee;Chair, ACTION Registry SteeringCommittee. Non-financial support istravel reimbursement.American College of Cardiology Belvoir Publications Editor in Chief, Harvard Heart LetterSlack Publications Chief Medical Editor, CardiologyToday’s InterventionWebMD CME Steering CommitteesElsevier Advisory Board, Elsevier PracticeUpdate CardiologyMedscape Cardiology Advisory BoardRegado Biosciences Advisory BoardBhatt3

ICMJE Form for Disclosure of Potential Conflicts of Interest Boston VA Research InstituteSociety of Cardiovascular Patient Care Board of Directors; Secretary/Treasurer. Non-financial support istravel reimbursement. Chair, American Heart AssociationQuality Oversight Committee. Nonfinancial support is travelreimbursement.American Heart AssociationHMP GlobalRocheEditor in Chief, Journal of InvasiveCardiology Research Funding; PIHarvard Clinical Research Institute (now BaimInstitute for Clinical Research)Executive Steering Committee for atrial funded by Boehringer Ingelheim(RE-DUAL PCI); Data MonitoringCommittee Chair for a trial funded bySt. Jude, now Abbott (PORTICO);Executive Committee for a trialfunded by CSL Behring (AEGIS-II) Clinical Cardiology Journal of the American College of CardiologyBoard of DirectorsDeputy EditorGuest Editor; Associate EditorVA Chair, VA Cardiovascular Assessment,Reporting and Tracking System(CART) Program, Research andPublications CommitteePfizer Research Funding; steeringcommitteeForest Laboratories/AstraZeneca Research Funding; Clinical EventsCommittee Chair for ASCENT COPDIschemix Research Funding; PISt. Jude Medical (now Abbott) Site Co-investigatorBiotronik Site Co-investigator Scientific Advisory Board Site Co-investigatorCardax Boston ScientificAmgen Research Funding; GOULD steeringcommitteeLilly Research Funding; steeringcommitteeChiesi Research Funding; co-PI and co-Chairof CHAMPION PHOENIXIronwood Research FundingCleveland Clinic BhattData Monitoring Committee,including for the ExCEED trial, fundedby Edwards4

ICMJE Form for Disclosure of Potential Conflicts of InterestMount Sinai School of MedicineData Monitoring Committee for theENVISAGE trial, funded by DaiichiSankyo MerckUnfunded research collaborationAbbott Research Funding; XIENCE ST DAPTExecutive CommitteeRegeneron Research Funding; ODYSSEYExecutive Steering CommitteeSvelte Site Co-investigator Research Funding; Scientific AdvisoryBoardPhaseBio Idorsia Research FundingSynaptic Research FundingTobeSoft Board of Directors Executive Steering Committee fortrial funded by Boehringer Ingelheim(RE-DUAL PCI) with payments fromHarvard Clinical Research Institute(now Baim Institute for ClinicalResearch); editorial support serviceslimited to collation of coauthorcomments and formatting; Researchfunding for Executive Committee forEMPACT-MIBoehringer Ingelheim BayerOperations Committee, PublicationsCommittee, USA co-National Leader,and Steering Committee for a trialfunded by Bayer (COMPASS), withpayments to Population HealthResearch Institute Novo Nordisk Fractyl Medtelligence/ReachMDResearch Funding CME Steering Committees Executive Committee for a trialfunded by CSL Behring (AEGIS-II) withpayments from Baim Institute forClinical ResearchCSL Behring Cereno ScientificAfimmuneBhatt Unfunded research collaboration;editorial support services limited tocollation of coauthor comments andformattingScientific Advisory BoardResearch Funding5

ICMJE Form for Disclosure of Potential Conflicts of InterestFerring PharmaceuticalsSteering Committee for thePRONOUNCE trial funded by FerringPharmaceuticals, with payments toDuke Clinical Research Institute CSI LexiconSite Co-investigatorSCORED and SOLOIST ChairMJH Life Sciences Educational programsLevel Ex Scientific Advisory BoardContego Medical DSMB Chair, PERFORMANCE 2CellProthera Scientific Advisory BoardK2P Co-Chair, Interdisciplinary CurriculumCanadian Medical and Surgical KnowledgeTranslation Research Group Clinical Trial and CME SteeringCommitteesMyoKardiaSection 4. Research Funding; Scientific AdvisoryBoardIntellectual Property -- Patents & CopyrightsDo you have any patents, whether planned, pending or issued, broadly relevant to the work?Section 5.Yes NoRelationships not covered aboveAre there other relationships or activities that readers could perceive to have influenced, or that give the appearance ofpotentially influencing, what you wrote in the submitted work?Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interestAt the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.On occasion, journals may ask authors to disclose further information about reported relationships.Bhatt6

ICMJE Form for Disclosure of Potential Conflicts of InterestSection 6.Disclosure StatementBased on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the boxbelow.Dr. Bhatt reports grants from Sanofi, grants from Lexicon Pharmaceuticals, during the conduct of the study; grants fromAmarin, grants from AstraZeneca, grants from Bristol-Myers Squibb, grants from Eisai, grants from Ethicon, grants fromMedtronic, grants from sanofi aventis, grants from The Medicines Company, other from FlowCo, grants and other from PLxPharma, other from Takeda, personal fees from Duke Clinical Research Institute, personal fees from Mayo Clinic, personalfees from Population Health Research Institute, personal fees, non-financial support and other from American College ofCardiology, personal fees from Belvoir Publications, personal fees from Slack Publications, personal fees from WebMD,personal fees from Elsevier, other from Medscape Cardiology, other from Regado Biosciences, other from Boston VAResearch Institute, personal fees and non-financial support from Society of Cardiovascular Patient Care, non-financialsupport from American Heart Association, personal fees from HMP Global, grants from Roche, personal fees from HarvardClinical Research Institute (now Baim Institute for Clinical Research), other from Clinical Cardiology, personal fees fromJournal of the American College of Cardiology, other from VA, grants from Pfizer, grants from Forest Laboratories/AstraZeneca, grants from Ischemix, other from St. Jude Medical (now Abbott), other from Biotronik, grants and other fromCardax, other from Boston Scientific, grants from Amgen, grants from Lilly, grants from Chiesi, grants from Ironwood,personal fees from Cleveland Clinic, personal fees from Mount Sinai School of Medicine, other from Merck, grants fromAbbott, grants from Regeneron, other from Svelte, grants and other from PhaseBio, grants from Idorsia, grants fromSynaptic, personal fees from TobeSoft, grants, personal fees and other from Boehringer Ingelheim, personal fees from Bayer,other from Novo Nordisk, grants from Fractyl, personal fees from Medtelligence/ReachMD, personal fees from CSL Behring,other from Cereno Scientific, grants from Afimmune, personal fees from Ferring Pharmaceuticals, other from CSI, grantsfrom Lexicon, personal fees from MJH Life Sciences, personal fees from Level Ex, personal fees from Contego Medical,personal fees from CellProthera, personal fees from K2P, personal fees from Canadian Medical and Surgical KnowledgeTranslation Research Group, grants and other from MyoKardia, outside the submitted work; .Dr. Bhatt reports grants fromAmarin, grants from AstraZeneca, grants from Bristol-Myers Squibb, grants from Eisai, grants from Ethicon, grants fromMedtronic, grants from sanofi aventis, grants from The Medicines Company, other from FlowCo, other from PLx Pharma,other from Takeda, personal fees from Duke Clinical Research Institute, personal fees from Mayo Clinic, personal fees fromPopulation Health Research Institute, personal fees, non-financial support and other from American College of Cardiology,personal fees from Belvoir Publications, personal fees from Slack Publications, personal fees from WebMD, personal feesfrom Elsevier, other from Medscape Cardiology, other from Regado Biosciences, other from Boston VA Research Institute,personal fees and non-financial support from Society of Cardiovascular Patient Care, non-financial support from AmericanHeart Association, personal fees from HMP Global, grants from Roche, personal fees from Harvard Clinical Research Institute(now Baim Institute for Clinical Research), other from Clinical Cardiology, personal fees from Journal of the AmericanCollege of Cardiology, other from VA, grants from Pfizer, grants from Forest Laboratories/AstraZeneca, grants fromIschemix, other from St. Jude Medical (now Abbott), other from Biotronik, other from Cardax, other from Boston Scientific,grants from Amgen, grants from Lilly, grants from Chiesi, grants from Ironwood, personal fees from Cleveland Clinic,personal fees from Mount Sinai School of Medicine, other from Merck, grants from Abbott, grants from Regeneron, otherfrom Svelte, grants and other from PhaseBio, grants from Idorsia, grants from Synaptic, personal fees from TobeSoft,personal fees and other from Boehringer Ingelheim, personal fees from Bayer, other from Novo Nordisk, grants from Fractyl,personal fees from Medtelligence/ReachMD, personal fees from CSL Behring, other from Cereno Scientific, grants fromAfimmune, personal fees from Ferring Pharmaceuticals, other from CSI, outside the submitted work; .Bhatt7

ICMJE Form for Disclosure of Potential Conflicts of InterestEvaluation and FeedbackPlease visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.Bhatt8

ICMJE Form for Disclosure of Potential Conflicts of InterestInstructionsThe purpose of this form is to provide readers of your manuscript with information about your other interests that couldinfluence how they receive and understand your work. The form is designed to be completed electronically and storedelectronically. It contains programming that allows appropriate data display. Each author should submit a separateform and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.1.Identifying information.2.The work under consideration for publication.This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of thework itself, from the initial conception and planning to the present. The requested information is about resources that you received,either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the workwithout receiving any financial support from any third party -- that is, the work was supported by funds from the same institution thatpays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received fundsfrom a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check"Yes".3.Relevant financial activities outside the submitted work.This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or thatgive the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entitythat could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor(EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancerin general, not just in the area of EGFR or lung cancer.Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior tosubmission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from theentity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted workshould also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could beperceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could beperceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations oracademic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involvedand drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.4.Intellectual Property.This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.5.Relationships not covered above.Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance ofpotentially influencing, what you wrote in the submitted work.Definitions.Entity: government agency, foundation, commercial sponsor,academic institution, etc.Grant: A grant from an entity, generally [but not always] paid to yourorganizationPersonal Fees: Monies paid to you for services rendered, generallyhonoraria, royalties, or fees for consulting , lectures, speakers bureaus,expert testimony, employment, or other affiliationsNon-Financial Support: Examples include drugs/equipmentsupplied by the entity, travel paid by the entity, writing assistance,administrative support, etc.CannonOther: Anything not covered under the previous three boxesPending: The patent has been filed but not issuedIssued: The patent has been issued by the agencyLicensed: The patent has been licensed to an entity, whetherearning royalties or notRoyalties: Funds are coming in to you or your institution due to yourpatent1

ICMJE Form for Disclosure of Potential Conflicts of InterestSection 1.Identifying Information1. Given Name (First Name)2. Surname (Last Name)3. DateChristopher P.Cannon25-September-2020Yes4. Are you the corresponding author? NoCorresponding Author’s NameDeepak Bhatt5. Manuscript TitleSotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure6. Manuscript Identifying Number (if you know it)20-30183Section 2.The Work Under Consideration for PublicationDid you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) forany aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation,statistical analysis, etc.)? YesAre there any relevant conflicts of interest?NoIf yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row.Excess rows can be removed by pressing the "X" button.Name of Institution/CompanyGrant? Personal Non-Financial OtherFees?Support? SanofiSection 3. CommentsGrant for trial, and consultancy feesRelevant financial activities outside the submitted work.Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amountof compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need byclicking the "Add " box. You should report relationships that were present during the 36 months prior to publication. YesAre there any relevant conflicts of interest?NoIf yes, please fill out the appropriate information below.Name of EntityGrant? Personal Non-Financial OtherFees?Support?CommentsAmgen Research grant and consultancy feesBoehringer Ingelheim Research grant and consultancy feesBristol-Myers Squibb Research grant and consultancy feesCannon2

ICMJE Form for Disclosure of Potential Conflicts of InterestGrant? Personal Non-Financial OtherFees?Support?Name of EntityDaiichi Sankyo Janssen ?CommentsResearch grant Research grant and consultancy feesAegerion Received consultancy feesAlnylam Received consultancy feesAmarin Received consultancy feesApplied Clinical Therapeutics Received consultancy feesAscendia Received consultancy feesCorvidia Received consultancy feesHLS Therapeutics Received consultancy feesInnovent Received consultancy feesKowa Received consultancy feesEli Lilly Received consultancy feesRhoshan Received consultancy feesPfizer Inc. Research grant and consultancy feesMerck and Co Research grant and consultancy feesSection 4.Intellectual Property -- Patents & CopyrightsDo you have any patents, whether planned, pending or issued, broadly relevant to the work?Section 5.Yes NoRelationships not covered aboveAre there other relationships or activities that readers could perceive to have influenced, or that give the appearance ofpotentially influencing, what you wrote in the submitted work?Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interestAt the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.On occasion, journals may ask authors to disclose further information about reported relationships.Cannon3

ICMJE Form for Disclosure of Potential Conflicts of InterestSection 6.Disclosure StatementBased on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the boxbelow.Dr. Cannon reports grants and personal fees from Sanofi, during the conduct of the study; grants and personal fees fromAmgen, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Bristol-Myers Squibb, grantsfrom Daiichi Sankyo, grants and personal fees from Janssen, personal fees from Aegerion, personal fees from Alnylam,personal fees from Amarin, personal fees from Applied Clinical Therapeutics, personal fees from Ascendia, personal feesfrom Corvidia, personal fees from HLS Therapeutics, personal fees from Innovent, personal fees from Kowa, personal feesfrom Eli Lilly , personal fees from Rhoshan, grants and personal fees from Pfizer Inc. , grants and personal fees from Merckand Co, outside the submitted work; .Evaluation and FeedbackPlease visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.Cannon4

ICMJE Form for Disclosure of Potential Conflicts of InterestInstructionsThe purpose of this form is to provide readers of your manuscript with information about your other interests that couldinfluence how they receive and understand your work. The form is designed to be completed electronically and storedelectronically. It contains programming that allows appropriate data display. Each author should submit a separateform and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.1.Identifying information.2.The work under consideration for publication.This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of thework itself, from the initial conception and planning to the present. The requested information is about resources that you received,either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the workwithout receiving any financial support from any third party -- that is, the work was supported by funds from the same institution thatpays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received fundsfrom a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check"Yes".3.Relevant financial activities outside the submitted work.This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or thatgive the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entitythat could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor(EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancerin general, not just in the area of EGFR or lung cancer.Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior tosubmission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from theentity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted workshould also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could beperceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could beperceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations oracademic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involvedand drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.4.Intellectual Property.This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.5.Relationships not covered above.Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance ofpotentially influencing, what you wrote in the submitted work.Definitions.Entity: government agency, foundation, commercial sponsor,academic institution, etc.Grant: A grant from an entity, generally [but not always] paid to yourorganizationPersonal Fees: Monies paid to you for services rendered, generallyhonoraria, royalties, or fees for consulting , lectures, speakers bureaus,expert testimony, employment, or other affiliationsNon-Financial Support: Examples include drugs/eq

ICMJE Form for Disclosure of Potential Conflicts of Interest Bhatt 2 Section 1. Identifying Information